Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance

Bristol-Myers Squibb CoTrade
iShares MSCI United Kingdom (FTSE)Trade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs iShares MSCI United Kingdom (FTSE) — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while iShares MSCI United Kingdom (FTSE) trades at $46.31. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares MSCI United Kingdom (FTSE) pays none. Which is the better fit depends on your goals.

BMYEWU
Market Cap
$116.30B
Sector
HealthBroad Market / Factor
52-Week High
$62.37$48.68
52-Week Low
$42.60$39.59
Enterprise Value
$152.24B
Dividend Yield
4.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

iShares MSCI United Kingdom (FTSE)

EWU, the iShares MSCI United Kingdom ETF, trades at $46.36, down 0.52% on the day, with technical indicators showing a neutral to bearish bias. The ETF's performance is heavily influenced by UK economic conditions and political developments, including recent leadership changes. Key holdings in financials, consumer staples, and healthcare drive its NAV, with the top 10 holdings comprising over half of the portfolio.

Outlook remains cautious due to UK political instability and economic headwinds, though potential exists from M&A activity and valuation discounts. Risks include sterling volatility and fiscal constraints. Analyst sentiment is mixed, reflecting uncertainty over near-term catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About iShares MSCI United Kingdom (FTSE)

EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.

Read more on EWU